Halozyme’s RHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable To Lispro | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com

MNT Diabetes News Health News

Halozyme Announces Positive Results From Roche's Subcutaneous Herceptin Phase 3 Trial

medicalnewstoday.com — “Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug de” View full resource at medicalnewstoday.com

Most Recently Shared on October 19, 2011 at 9:06 am By:

Halozyme Announces Positive Results From Roche's Subcutaneous Herceptin Phase 3 Trial http://t.co/oYjmFNW4 #diabetes

7 months ago...

News-Medical.Net Health News

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

news-medical.net — “ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.” View full resource at news-medical.net

Most Recently Shared on September 14, 2011 at 9:22 am By:

Epilepsy News: ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE: ViroPharma Incorpor... http://t.co/gtuN5A0

9 months ago...

Drugs and Devices OW OW Health

Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency - Drugs.com MedNews

drugs.com — “Jul 8, 2011 - Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilit” View full resource at drugs.com

Most Recently Shared on July 8, 2011 at 7:24 pm By:

Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodef... http://bit.ly/nFpidQ #drug

Healthy Society Health News

Halozyme keeps options open for ultrafast insulin

healthsociety.visibli.com — “Halozyme keeps options open for ultrafast insulin” View full resource at healthsociety.visibli.com

Most Recently Shared on June 27, 2011 at 12:40 am By:

Halozyme keeps options open for ultrafast insulin http://bit.ly/jPGSS7

MedicalFeed Health News Feed

Halozyme keeps options open for ultrafast insulin - QualityPoint Technologies

qualitypointtech.net — “SAN DIEGO (Reuters) - Halozyme Therapeutics Inc, which specializes in reformulating drug products available only as infusions, expects to have key results this fall from trials of its” View full resource at qualitypointtech.net

Most Recently Shared on June 26, 2011 at 11:00 pm By:

Halozyme keeps options open for ultrafast insulin: SAN DIEGO (Reuters) - Halozyme Therapeutics Inc, which speciali... http://bit.ly/k2uk9G

Halozyme keeps options open for ultrafast insulin

health.yahoo.net — “Halozyme Therapeutics Inc, which specializes in reformulating drug products available only as infusions, expects to have key results this fall from trials of its "ultrafast" insulin formulations.” View full resource at health.yahoo.net

Most Recently Shared on June 26, 2011 at 10:29 pm By:

Jennifer Ann Grisso Nurse and Active Health Library

Halozyme keeps options open for ultrafast insulin: Halozyme Therapeutics Inc, which specializes in reformulating... http://bit.ly/mAolxq

Ellen H Ullman Social Worker

Halozyme's Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps - KSWO, Lawton, OK- Wichita Falls, TX: News, Weather, Sports. ABC, 24/7, Telemundo -

kswo.com — “KSWO-TV 7 News is your source for news, weather and sports in Oklahoma and Texas, delivering breaking news, tracking storms and giving you the 7 day forecast.” View full resource at kswo.com

Most Recently Shared on June 25, 2011 at 1:17 am By:

Halozyme's Ultrafast Insulin DemosReduced Variability of Insulin Absorption Type 1 #Diabetes Patients on Insulin Pumps http://bit.ly/lst703

Ellen H Ullman Social Worker

Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions - 19 Action News|Cleveland, OH|Breaking News, Weather, Exclusives

woio.com — “19 Action News is your local source for information in Cleveland, OH, delivering breaking news, weather, sports and exclusive investigations” View full resource at woio.com

Most Recently Shared on June 20, 2011 at 9:42 pm By:

Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at Upcoming ADA Scientific Sessions http://bit.ly/kfrCPo #diabetes

Drugs and Devices OW OW Health

Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions - Drugs.com MedNews

drugs.com — “Halozyme Therapeutics, Inc. (Nasdaq HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announc” View full resource at drugs.com

Most Recently Shared on June 20, 2011 at 9:14 pm By:

Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes ... http://bit.ly/jf3GUV #drug

Ellen H Ullman Social Worker

Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes... -- SAN DIEGO, April 14, 2011 /PRNewswire/ --

prnewswire.com — “Halozyme's Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps. - Continuous subcutaneous infusion of insulin with rHuPH20 in pumps demonstrated the ultra rapid profile previously observed with Aspart-PH20 injections -.” View full resource at prnewswire.com

Most Recently Shared on April 15, 2011 at 2:15 am By:

Halozyme's Ultrafast Insulin Generates Faster-In &Faster-Out Profile-Type 1 Diabetes Patients w/Insulin Pump http://prn.to/e8rLSS #diabetes

Endocrinology Wisdom OW Health

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

news-medical.net — “Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.” View full resource at news-medical.net

Most Recently Shared on March 11, 2011 at 2:49 pm By:

Halozyme Therapeutics 2010 net loss decreases to $53.2 million: Halozyme Therapeutics, Inc., a biopharmaceutical... http://bit.ly/hnLJMW

Phase 3 study of MabThera for the treatment of non-Hodgkin's lymphoma - MPR

empr.com — “Halozyme Therapeutics and Roche announced initiation of their Phase 3 study of subcutaneous MabThera (rituximab) for the treatment of NHL.” View full resource at empr.com

Most Recently Shared on February 16, 2011 at 4:28 pm By:

MPR Medical Publisher

MPR News: Phase 3 study of MabThera for the treatment of non-Hodgkin's lymphoma: Halozyme Therapeutics and Roche... http://bit.ly/fNo0Cu

OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher

Phase 2 study of Herceptin SC (subcutaneous) for the treatment of HER2-positive breast cancer - ONA

oncologynurseadvisor.com — “Halozyme Therapeutics announced that patient enrollment has been completed for a Phase 3 study of Herceptin SC (trastuzumab subcutaneous) for the treatment of HER2-positive breast cancer.” View full resource at oncologynurseadvisor.com

Most Recently Shared on December 15, 2010 at 7:56 pm By:

Phase 2 study of Herceptin SC (subcutaneous) for the treatment of HER2-positive breast cancer http://goo.gl/fb/jvHLY

Scott Strumello Patient Expert

- News, Search Jobs, Events

biospace.com — “- News, Search Jobs, Events” View full resource at biospace.com

Most Recently Shared on December 3, 2010 at 6:46 pm By:

Halozyme Therapeutics Realigns Management; Gregory I. Frost Becomes CEO After Jonathan E. Lim Resigns : http://bit.ly/dIiApU

Drugs and Devices OW OW Health

Halozyme Therapeutics Realigns Management - Drugs.com MedNews

drugs.com — “- Gregory I. Frost, Ph.D., appointed president and CEO - - Jonathan E. Lim, M.D., resigns as president, CEO and director - - H. Michael Shepard, Ph.D., promoted” View full resource at drugs.com

Most Recently Shared on December 3, 2010 at 6:05 pm By:

Halozyme Therapeutics Realigns Management: - Gregory I. Frost, Ph.D., appointed president and CEO - - Jona... http://bit.ly/eioPyw #drug